Palisade Bio (NASDAQ:PALI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Palisade Bio (NASDAQ:PALI) from a sell rating to a hold rating in a research report report published on Saturday.

Other research analysts have also recently issued research reports about the stock. Clear Str upgraded shares of Palisade Bio to a “strong-buy” rating in a research note on Monday, December 29th. B. Riley Financial assumed coverage on Palisade Bio in a research report on Friday, January 9th. They issued a “buy” rating and a $7.00 price objective for the company. Citigroup reissued a “buy” rating on shares of Palisade Bio in a research note on Tuesday, November 11th. Piper Sandler assumed coverage on Palisade Bio in a research note on Monday, December 29th. They issued an “overweight” rating and a $25.00 target price for the company. Finally, Stifel Nicolaus began coverage on shares of Palisade Bio in a report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.25.

Palisade Bio Stock Up 2.3%

Shares of PALI opened at $1.81 on Friday. The company has a 50-day moving average price of $1.86 and a two-hundred day moving average price of $1.60. The stock has a market cap of $269.69 million, a price-to-earnings ratio of -0.85 and a beta of 1.53. Palisade Bio has a 12 month low of $0.53 and a 12 month high of $2.64.

Institutional Investors Weigh In On Palisade Bio

Hedge funds have recently bought and sold shares of the company. Perceptive Advisors LLC bought a new position in Palisade Bio during the fourth quarter worth about $28,318,000. Commodore Capital LP acquired a new position in shares of Palisade Bio in the 4th quarter valued at approximately $26,896,000. Janus Henderson Group PLC acquired a new position in shares of Palisade Bio in the 4th quarter valued at approximately $24,822,000. RA Capital Management L.P. bought a new stake in Palisade Bio during the 4th quarter worth approximately $16,742,000. Finally, Eversept Partners LP acquired a new stake in Palisade Bio during the 4th quarter worth approximately $12,670,000. 11.79% of the stock is currently owned by institutional investors and hedge funds.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.